Get the Stockscreener App
4.26
66.41%
1.70
Pre-market:
4.35
0.09
+2.11%
Perspective Therapeutics Inc stock is traded at $4.26, with a volume of 79.97M.
It is up +66.41% in the last 24 hours and up +56.04% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$2.56
Open:
$2.59
24h Volume:
79.97M
Relative Volume:
30.09
Market Cap:
$316.68M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-24.83
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+59.55%
1M Performance:
+56.04%
6M Performance:
+8.67%
1Y Performance:
+18.01%
1-Day Range:
$2.56
$6.16
1-Week Range:
$2.55
$6.16
52-Week Range:
$1.60
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
4.26 | 190.31M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
106.09 | 184.41B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
92.33 | 139.09B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.30 | 136.84B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.00 | 129.21B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
81.49 | 47.50B | 5.88B | 1.34B | 799.60M | 2.3489 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Perspective Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
Perspective Therapeutics stock (CATX) steadies before the open after 66% jump — what investors watch next - TechStock²
Growth Report: Does Perspective Therapeutics Inc stock have upside surprise potential2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4%Time to Sell? - MarketBeat
Can Perspective Therapeutics Inc expand into new marketsQuarterly Trade Review & Precise Buy Zone Identification - baoquankhu1.vn
Signal Recap: Whats the MACD signal for APLSPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Reviewing Perspective Therapeutics (NASDAQ:CATX) & CapsoVision (NASDAQ:CV) - Defense World
Analyzing Carlsmed (NASDAQ:CARL) and Perspective Therapeutics (NASDAQ:CATX) - Defense World
Aug Momentum: Is Perspective Therapeutics Inc part of any major indexRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
CEO Moves: Is Perspective Therapeutics Inc part of any major indexMarket Performance Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Critical Contrast: Perspective Therapeutics (NASDAQ:CATX) and Shoulder Innovations (NYSE:SI) - Defense World
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets
Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat
Short Covering: Can Perspective Therapeutics Inc generate free cash flowEarnings Overview Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks
Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView
Perspective Therapeutics Provides Business Updates and - GlobeNewswire
How Perspective Therapeutics Inc. stock benefits from global expansionPerformance Line Overview & walk-ready comfort choices - Улправда
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Experimental targeted radiation shows tumor shrinkage in early trial - Stock Titan
Will Perspective Therapeutics Inc. stock attract ESG investorsEarnings Recap Summary & Weekly High Potential Stock Alerts - Улправда
Why Perspective Therapeutics Inc. stock could see breakout soonQuarterly Earnings Report & Verified Swing Trading Watchlists - Улправда
Published on: 2026-01-08 23:03:38 - Улправда
Will Perspective Therapeutics Inc. stock continue upward momentum2025 Biggest Moves & Reliable Entry Point Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Why Perspective Therapeutics Inc. stock remains a top recommendationFederal Reserve Announcements & Investor Community Interactions - bollywoodhelpline.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4%Should You Buy? - MarketBeat
Market Review: Will Perspective Therapeutics Inc stock continue upward momentumTrend Reversal & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Perspective Therapeutics (FRA:AAJ0) EV-to-OCF : -0.36 (As of Dec. 26, 2025) - GuruFocus
Aug Decliners: How Perspective Therapeutics Inc AAJ0 stock benefits from digital adoption2025 Stock Rankings & Daily Stock Trend Watchlist - moha.gov.vn
Perspective Therapeutics Inc Stock Analysis and ForecastRisk Management Strategies & Affordable Portfolio Tips - earlytimes.in
Can Perspective Therapeutics Inc. stock resist market sell offsWeekly Investment Recap & Weekly Momentum Picks - Улправда
Aug EndMonth: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockWeekly Profit Recap & Proven Capital Preservation Methods - Улправда
Perspective Therapeutics Earnings Notes - Trefis
How Perspective Therapeutics Inc. stock valuations compare to rivalsMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Published on: 2025-12-20 05:01:39 - Улправда
Market Review: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Trading Recap: How Perspective Therapeutics Inc. stock valuations compare to rivals2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Is Perspective Therapeutics Inc. stock in correction or buying zone2025 Fundamental Recap & Growth Focused Stock Reports - DonanımHaber
How Perspective Therapeutics Inc. (AAJ0) stock benefits from digital adoptionInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
How Perspective Therapeutics Inc. stock compares to market leadersEarnings Growth Report & Community Supported Trade Ideas - DonanımHaber
Should I buy Perspective Therapeutics Inc. stock before earnings seasonJuly 2025 Spike Watch & Smart Investment Allocation Insights - Улправда
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Perspective Therapeutics, Inc. (CATX) 6.37% in After-hours: Stock Rises Amid Increased Investor Engagement - Stocks Telegraph
EV Market: How strong is Perspective Therapeutics Inc stock earnings growthTrade Signal Summary & Precise Buy Zone Identification - moha.gov.vn
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.30%
Cap:
|
Volume (24h):